NEJM Journal Watch Oncology and Hematology Top Stories of 2020

Highlights of the most important research from the past year

Dear Readers,

This year, our list of NEJM Journal Watch Oncology and Hematology top stories includes coverage of studies on breast, gastrointestinal, genitourinary, and lung cancers as well as malignant and benign hematology. These summaries underscore our goal of identifying the most clinically relevant trials and highlighting their key findings and implications. We look forward to continuing to bring you concise summaries of the most important research in oncology and hematology during the coming year.

Our oncology and hematology top 10 stories of 2020 are as follows:

Triplet Therapy for HER2+ Metastatic Breast Cancer and Brain Metastases

Bevacizumab plus Atezolizumab for Advanced Hepatocellular Cancer

Trastuzumab Deruxtecan for Previously Treated HER2+ Gastric Cancer

Avelumab Maintenance Therapy for Metastatic Urothelial Cancer

Olaparib for Men with Metastatic Castration-Resistant Prostate Cancer

Adjuvant Osimertinib for Resected EGFR-Mutated Non–Small-Cell Lung Cancer

Azacitidine plus Venetoclax for Acute Myeloid Leukemia

An Emerging Treatment for Acute Graft-Versus-Host Disease

COVID-19 Coagulopathy: Excess Thrombosis and Bleeding?

Apixaban vs. Dalteparin for Cancer-Associated Venous Thromboembolism

Author

William J. Gradishar, MD

Disclosures

Consultant/Advisory BoardLilly; AstraZeneca; Gilead

Grant/Research SupportBreast Cancer Research Foundation

Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment

Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)